Male breast cancer: Genetics, epigenetics, and ethical aspects

Annals of Oncology

Volumn 24, Issue SUPPL.B, 2013, Pages

  Rizzolo, P ^a   Silvestri, V ^a   Tommasi, S ^b   Pinto, R ^b   Danza, K ^b   Falchetti, M ^a   Gulino, M ^c   Frati, P ^c,d   Ottini, L ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b National Cancer Research Centre   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

Epigenetic alterations; Ethics; Genetic susceptibility; Male breast cancer; Methylation; MiRNAs

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; TUMOR MARKER;

ARTICLE; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER GENETICS; CANCER PATIENT; CANCER RESEARCH; CANCER RISK; CANCER SUSCEPTIBILITY; DIAGNOSTIC TEST; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE; GENE DELETION; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENE INSERTION; GENE MUTATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; MALE; MALE BREAST CANCER; MEDICAL ETHICS; MUTATIONAL ANALYSIS; PALB2 GENE; PATIENT CARE; PENETRANCE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RASSF1A GENE; TUMOR SUPPRESSOR GENE; XRCC2 GENE;

EPIGENETIC ALTERATIONS; ETHICS; GENETIC SUSCEPTIBILITY; MALE BREAST CANCER; METHYLATION; MIRNAS;

BREAST NEOPLASMS, MALE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICRORNAS;

EID: 84886297009     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt316     Document Type: Article

References (99)

1. Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat 2009; 115: 429-430.
2. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Ottini L, Palli D, Rizzo S et al. Male breast cancer. Crit Rev Oncol Hematol 2010; 73: 141-155.
4. Ly D, Forman D, Ferlay J et al. An international comparison of male and female breast cancer incidence rates. Int J Cancer 2013; 132(8): 1918-1926.
5. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004; 9: 221-236.
6. Korde LA, Zujewski JA, Kamin L et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J ClinOncol 2010; 28: 2114-2122.
7. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-298.
8. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009; 10: 704-714.
9. Shen J, Ambrosone CB, Zhao H. Novel genetic variants in microRNA genes and familial breast cancer. Int J Cancer 2009; 124: 1178-1182.
10. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 2009; 28: 369-378.
11. Willems PG. Susceptibility genes in breast cancer: more is less? Clin Genet 2007; 72: 493-496.
12. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008; 40: 17-22.
13. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
14. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20: 1480-1490.
15. Ottini L, Silvestri V, Rizzolo P et al. Clinical and pathologic characteristics of BRCApositive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat 2012; 134: 411-418.
16. Durocher F, Shattuck-Eidens D, McClure M et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet 1996; 5: 835-842.
17. Giannini G, Capalbo C, Ottini L et al. Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain. J Clin Oncol 2008; 26: 4212-4214.
18. Qiu LX, Yao L, Xue K et al. BRCA2 N372h polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects. Breast Cancer Res Treat 2010; 123: 487-490.
19. Palli D, Falchetti M, Masala G et al. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy. BMC Cancer 2007; 7: 170.
20. Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185-187.
21. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408.
22. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005; 10(7): 471-479.
23. Ottini L, Rizzolo P, Zanna I et al. BRCA1/BRCA2 Mutation status and clinicalpathologic features of 108 male breast cancer cases from Tuscany: a populationbased study in central Italy. Breast Cancer Res Treat 2009; 116: 577-586.
24. Papi L, Putignano AL, Congregati C et al. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat 2009; 117: 497-504.
25. Sluiter MD, van Rensburg EJ. Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat 2011; 125: 325-349.
26. Hansen TO, Jønson L, Albrechtsen A et al. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families. Breast Cancer Res Treat 2009; 115: 315-323.
27. Karhu R, Laurila E, Kallioniemi A et al. Large genomic BRCA2 rearrangements and male breast cancer. Cancer Detect Prev 2006; 30: 530-534.
28. Capalbo C, Buffone A, Vestri A et al. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction? J Clin Oncol 2007; 25(18): 2632-2634.
29. Tournier I, Paillerets BB, Sobol H et al. Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 2004; 64: 8143-8147.
30. Falchetti M, Lupi R, Rizzolo P et al. BRCA1/BRCA2 Rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 2008; 110: 161-167.
31. Vargas AC, Reis-Filho JS, Lakhani SR. Phenotype-genotype correlation in familial breast cancer. J Mammary Gland Biol Neoplasia 2011; 16: 27-40.
32. Honrado E, Osorio A, Palacios J et al. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 2006; 25: 5837-5845.
33. Bane AL, Beck JC, Bleiweiss I et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2006; 31: 121-128.
34. Da Silva L, Lakhani SR. Pathology of hereditary breast cancer. Mod Pathol 2010; 23(Suppl 2): S46-S51.
35. Mavaddat N, Barrowdale D, Andrulis IL et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-147.
36. Tirkkonen M, Kainu T, Loman N et al. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer 1999; 24: 56-61.
37. Tommasi S, Mangia A, Iannelli G et al. Gene copy number variation in male breast cancer by aCGH. Anal Cell Pathol 2010; 33: 113-119.
38. Meijers-Heijboer H, van den Ouweland A, Klijn J et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-59.
39. Neuhausen S, Dunning A, Steele L et al. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 2004; 108: 477-478.
40. Ohayon T, Gal I, Baruch RG et al. CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004; 108: 479-480.
41. Syrjäkoski K, Kuukasjärvi T, Auvinen A et al. CHEK2 1100delc is not a risk factor for male breast cancer population. Int J Cancer 2004; 108: 475-476.
42. Martinez-Bouzas C, Beristain E, Guerra I et al. CHEK2 1100delc is present in familial breast cancer cases of the basque country. Breast Cancer Res Treat 2007; 103: 111-113.
43. Narod SA, Lynch HT. CHEK2 Mutation and hereditary breast cancer. J Clin Oncol 2007; 25: 6-7.
44. Caligo MA, Agata S, Aceto G et al. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mutat 2004; 24: 100-101.
45. Levy-Lahad E. Fanconi anemia and breast cancer susceptibility meet again. Nat Genet 2010; 42: 368-369.
46. Rahman N, Seal S, Thompson D et al. PALB2, Which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165-167.
47. García MJ, Fernández V, Osorio A et al. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat. 2009; 113: 545-551.
48. Casadei S, Norquist BM, Walsh T et al. Contribution to familial breast cancer of inherited mutations in the BRCA2-interacting protein PALB2. Cancer Res 2011; 71: 2222-2229.
49. Erkko H, Xia B, Nikkilä J et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 2007; 446: 316-319.
50. Sauty de Chalon A, Teo Z, Park DJ et al. Are PALB2 mutations associated with increased risk of male breast cancer? Breast Cancer Res Treat 2010; 121: 253-255.
51. Silvestri V, Rizzolo P, Zanna I et al. PALB2 Mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat 2010; 122: 299-301.
52. Adank MA, van Mil SE, Gille JJ et al. PALB2 Analysis in BRCA2-like families. Breast Cancer Res Treat. 2010; 127: 357-362.
53. Ding YC, Steele L, Kuan CJ et al. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat 2011; 126: 771-778.
54. Silvestri V, Rizzolo P, Falchetti M et al. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy. Breast Cancer Res Treat 2011; 126: 539-543.
55. Meindl A, Hellebrand H, Wiek C et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-414.
56. Silvestri V, Rizzolo P, Falchetti M et al. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res 2011; 13: 404.
57. Park DJ, Lesueur F, Nguyen-Dumont T et al. Rare mutations in XRCC2increase the risk of breast cancer. Am J Hum Genet 2012; 90: 734-739.
58. Pharoah PD, Antoniou A, Bobrow M et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33-36.
59. Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 2006; 98: 1382-1396.
60. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093.
61. Cox A, Dunning AM, Garcia-Closas M et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007; 39: 352-358.
62. Stacey SN, Manolescu A, Sulem P et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008; 40: 703-706.
63. Thomas G, Jacobs KB, Kraft P et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009; 41: 579-584.
64. Zheng W, Long J, Gao YT et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009; 41: 324-328.
65. Turnbull C, Ahmed S, Morrison J et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010; 42: 504-507.
66. Ghoussaini M, Fletcher O, Michailidou K et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012; 44: 312-318.
67. Fletcher O, Houlston RS. Architecture of inherited susceptibility to common cancer. Nat Rev Cancer 2010; 10: 353-361.
68. Mavaddat N, Antoniou AC, Easton DF et al. Genetic susceptibility to breast cancer. Mol Oncol 2010; 4: 174-191.
69. Antoniou AC, Spurdle AB, Sinilnikova OM et al. Common breast cancerpredisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008; 82: 937-948.
70. Wasserman NF, Aneas I, Nobrega MA. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res 2010; 20: 1191-1197.
71. Ghoussaini M, Song H, Koessler T et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008; 100: 962-966.
72. Wokolorczyk D, Gliniewicz B, Sikorski A et al. A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 2008; 68: 9982-9986.
73. Wokołorczyk D, Lubiński J, Narod SA et .al ćGenetic heterogeneity of 8q24 region in susceptibility to cancer. J Natl Cancer Inst 2009; 101: 278-279.
74. Bonifaci N, Górski B, Masojć B et al. Exploring the link between germline and somatic genetic alterations in breast carcinogenesis. PLoS One 2010; 5: e14078.
75. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008; 14: 8000-8009.
76. Orr N, Cooke R, Jones M et al. Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men. PLoS Genet 2011; 7: e1002290.
77. Orr N, Lemnrau A, Cooke R et al. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet 2012; 44(11): 1182-1184.
78. Holliday R. The inheritance of epigenetic defects. Science 1987; 238: 163-170.
79. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010; 15: 5-17.
80. Robertson KD, Uzvolgyi E, Liang G et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999; 27: 2291-2298.
81. Girault I, Tozlu S, Lidereau R et al. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003; 9: 4415-4422.
82. Xiang TX, Yuan Y, Li LL et al. Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer 2011; 32(1): 12-20.
83. Jovanovic J, Ronneberg JA, Tost J et al. The epigenetics of breast cancer. Mol Oncol 2010; 4: 242-254.
84. Kornegoor R, Moelans CB, Verschuur-Maes AH et al. Promoter hypermethylation in male breast cancer: analysis by multiplex ligation-dependent probe amplification. Breast Cancer Res 2012; 14: R101.
85. Thaler S, Schmidt M, Schad A et al. RASSF1A Inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development. Oncogene 2012; 31(47): 4912-4922.
86. Pinto R, Pilato B, Ottini L et al. Different methylation and microRNA expression pattern in male and female familial breast cancer. J Cell Physiol 2013; 228(6): 1264-1269.
87. Kumar A, Wong AK, Tizard ML et al. miRNA_targets: a database for miRNA target predictions in coding and non-coding regions of mRNAs. Genomics 2012; 100(6): 352-356.
88. Tsai NP, Lin YL, Wei LN. MicroRNA mir-346 targets the 50-untranslated region of receptor-interacting protein 140 (RIP140) mRNA and up-regulates its protein expression. Biochem J 2009; 424: 411-418.
89. Issabekova A, Berillo O, Regnier M et al. Interactions of intergenic microRNAs with mRNAs of genes involved in carcinogenesis. Bioinformation 2012; 8: 513-518.
90. Ling H, Zhang W, Calin GA. Principles of microRNA involvement in human cancers. Chin J Cancer 2011; 30: 739-748.
91. Li M, Li J, Ding J et al. microRNA and cancer. AAPS J 2010; 12: 309-317.
92. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
93. Fassan M, Baffa R, Palazzo JP et al. MicroRNA expression profiling of male breast cancer. Breast Cancer Res 2009; 11: R58.
94. Lehmann U, Streichert T, Otto B et al. Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer 2010; 10: 109.
95. Corcoran C, Friel AM, Duffy MJ et al. Intracellular and extracellular microRNAs in breast cancer. Clin Chem 2011; 57: 18-32.
96. Offit K. Personalized medicine: new genomics, old lessons. Hum Genet 2011; 130: 3-14.
97. France L, Michie S, Barrett-Lee P et al. Male cancer: a qualitative study of male breast cancer. Breast 2000; 9: 343-348.
98. Bunnik EM, Schermer MH, Janssens AC. The role of disease characteristics in the ethical debate on personal genome testing. BMC Med Genomics 2012; 5: 4.
99. Tan DS, Marchiò C, Reis-Filho JS. Hereditary breast cancer: from molecular pathology to tailored therapies. J Clin Pathol 2008; 61: 1073-1082.